{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:49:18Z","timestamp":1790880558803,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.farma.2024.03.008","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T20:12:35Z","timestamp":1714248755000},"page":"222-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-9265","authenticated-orcid":false,"given":"Antonio","family":"Garcia Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.farma.2024.03.008_bb0005","first-page":"80","article-title":"An\u00e1lisis descriptivo de pacientes con leucemia mieloide cr\u00f3nica de una IPS de Cali","volume":"21","author":"Cortes","year":"2017","journal-title":"Rev Colomb Cancerol."},{"issue":"3","key":"10.1016\/j.farma.2024.03.008_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1998.01033.x","article-title":"Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia","volume":"103","author":"Lichty","year":"1998","journal-title":"Br J Haematol."},{"issue":"24","key":"10.1016\/j.farma.2024.03.008_bb0015","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med."},{"issue":"24","key":"10.1016\/j.farma.2024.03.008_bb0020","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.farma.2024.03.008_bb0025","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.farma.2024.03.008_bb0030","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.farma.2024.03.008_bb0035","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.farma.2024.03.008_bb0040","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1007\/s00432-022-04562-5","article-title":"Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors","volume":"149","author":"Atallah","year":"2023","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1016\/j.farma.2024.03.008_bb0045","series-title":"NCCN Guidelines Version 2.2024 Chronic Myeloid Leukemia Continue NCCN Guidelines Panel Disclosures","author":"Kristina Gregory","year":"2023"},{"key":"10.1016\/j.farma.2024.03.008_bb0050","author":"National Cancer Institute SCS"},{"issue":"8","key":"10.1016\/j.farma.2024.03.008_bb0055","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40273-018-0627-4","article-title":"Ponatinib for treating chronic myeloid leukaemia: an evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Pandor","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.farma.2024.03.008_bb0060","author":"Gobierno de Aragon"},{"key":"10.1016\/j.farma.2024.03.008_bb0065","author":"NICE"},{"key":"10.1016\/j.farma.2024.03.008_bb0070","series-title":"Gu\u00eda GENESIS de Evaluaci\u00f3n Econ\u00f3mica e Impacto Presupuestario En Los Informes de Evaluaci\u00f3n de Medicamentos","author":"Ortega Eslava Roberto Mar\u00edn Gil Ma Dolores Fraga Fuentes Eduardo L\u00f3pez-Briz Francesc Puigvent\u00f3s Latorre A","year":"2016"},{"issue":"4","key":"10.1016\/j.farma.2024.03.008_bb0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.farma.2024.03.008_bb0080","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.farma.2024.03.008_bb0085","author":"Ministerio de Sanidad"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:39:16Z","timestamp":1726360756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1130634324000448"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.03.008","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}